Managing Partner

Thomas Axel Haag, Ph.D., J.D.

Thomas is Managing Partner of Linden Lake Venture Capital. He is a biotechnology investor, entrepreneur and intellectual property lawyer. Most recently he was CEO of Linden Lake portfolio company, AexeRNA Therapeutics, a next-generation mRNA lipid nanoparticle technology company he co-founded with the late Michael Buschmann of George Mason University and Drew Weissman at the University of Pennsylvania. AexeRNA was acquired by a large publicly traded biotechnology company. He also served as CEO of Linden Lake portfolio company C-Reveal Therapeutics, an immuno-oncology therapeutics company spun out of the Massachusetts General Hospital and Harvard Medical School co-founded with Mark Cobbold, Pam Sharma and Keith Flaherty. He was also a co-founder, and Interim CEO of PhosImmune, Inc., an immuno-oncology company co-founded with Donald Hunt at the University of Virginia and acquired by Agenus, Inc. (NASDAQ: AGEN).

During his legal career he served as partner and co-Chair of Seyfarth Shaw LLP’s Life Sciences IP Practice. Prior to its acquisition by Seyfarth, he was Chair of Fanelli Haag PLLC a preeminent life sciences focused D.C. law firm. Thomas was also General Counsel of Arrowhead Research Corporation (NASDAQ: ARWR). While at Arrowhead he also served as CEO of Tego Biosciences, an ARWR portfolio company, which was acquired by Luna Innovations (NASDAQ: LUNA). He graduated from The George Washington University Law School. He earned a B.S. in Biology and Ph.D. in Molecular, Cell & Developmental Biology from UCLA where he was an NIH Pre-doctoral Fellow in Genetics.

Strategic Advisors

Linden Lake’s has an extensive network of Strategic Advisors are veteran biotechnology experts that provide us with direct, industry-relevant insights and access to leading bio-pharmaceutical companies, as well as counsel and guidance in our investment decisions.